Anti-Mouse CD155 (PVR) [Clone 4.24.1] — Purified in vivo GOLD™ Functional Grade

Clone 4.24.1 is a rat anti-mouse CD155 monoclonal antibody widely used in preclinical research for investigating CD155-mediated immune responses in living mice. This antibody has several important in vivo applications centered around modulating immune checkpoint pathways and tumor immunity.

Functional Blockade of CD155 Pathways

Researchers employ clone 4.24.1 primarily for functional blockade or modulation of CD155-mediated pathways in living mice. This includes analyzing immune cell engagement, tumor immunity, and receptor-ligand interactions between CD155 and immune effectors. The antibody effectively disrupts the CD155 signaling axis, which plays crucial roles in both immune activation and suppression.

Cancer Immunotherapy Research

Clone 4.24.1 has been extensively used in tumor immunity studies and therapeutic interventions. The antibody has been applied in monitoring tumor burden in mice, particularly in graft-versus-host disease (GVHD) models. Recent studies have utilized this clone in combination therapies, such as with synNotch-programmed iPSC-derived NK cells targeting TIGIT and CD155 pathways. These applications leverage the antibody's ability to block CD155 interactions with inhibitory receptors like TIGIT, potentially enhancing anti-tumor immune responses.

Target Recognition and Distribution

Clone 4.24.1 recognizes a specific epitope on mouse CD155, a transmembrane glycoprotein expressed at cell junctions on primary vascular endothelium. This distribution pattern makes it particularly useful for studying vascular biology and tumor microenvironment interactions. The antibody's high specificity (>95% purity by SDS-PAGE) and low endotoxin levels (≤1.0 EU/mg) make it suitable for sensitive in vivo experiments requiring functional-grade reagents.

Experimental Advantages

The clone is manufactured using animal-free, in vitro protein-free cell culture techniques and purified through multi-step processes to ensure extremely low endotoxin levels and minimal protein aggregates. These characteristics are essential for in vivo applications where contamination or non-specific effects could confound experimental results.

Based on the available information, 4.24.1 is an antibody clone that recognizes mouse CD155 (also known as PVR, or poliovirus receptor). When used in research, particularly in cancer immunology studies, several antibodies and proteins are commonly employed alongside 4.24.1.

Common Co-Used Antibodies and Proteins

4-1BB agonist antibodies are frequently paired with the 4.24.1 antibody in the literature, especially in cancer research contexts. The 4.24.1 antibody functions as a CD155 targeting agent, and its use in combination with 4-1BB agonists relates to their complementary roles in modulating immune responses.

Relevant Interaction Partners

Given that CD155 serves as a key immune checkpoint molecule, antibodies targeting its natural binding partners are also relevant in experimental contexts:

CD226 (DNAM-1) - This is a natural ligand for CD155. The interaction between DNAM-1 and CD155 induces cytotoxicity of NK cells and CD8+ T cells, as well as cytokine secretion.

CD96 - Another receptor that interacts with CD155 to regulate NK cell and cytotoxic T lymphocyte (CTL) activity.

CD112 (nectin-2) - While not a direct CD155 antibody pairing, CD112 shares functional overlap with CD155 as both serve as ligands for DNAM-1 and participate in similar immune regulatory pathways.

These combinations reflect the broader investigation of immune checkpoint pathways and their manipulation for therapeutic purposes, particularly in cancer immunotherapy research where modulating CD155 interactions can affect tumor immunity.

Based on the available search results, there is limited information about key findings from clone 4.24.1 citations in scientific literature. However, I can provide what is known about this clone and its applications.

Clone 4.24.1 Overview

Clone 4.24.1 is a monoclonal antibody that specifically recognizes mouse CD155, also known as Poliovirus Receptor (PVR). This antibody is commonly used in in vivo mouse studies to functionally target CD155.

Biological Significance of the Target

CD155 is a transmembrane glycoprotein that belongs to the immunoglobulin-like adhesion receptor subfamily. Beyond its historical identification as the cellular receptor for poliovirus, CD155 plays important roles in immune regulation. The protein establishes intercellular adherens junctions between epithelial cells and interacts with both CD226 and CD96 to induce cytotoxicity of natural killer (NK) cells and cytotoxic T lymphocytes (CTL).

The interaction of CD226 (DNAM-1) with its ligands CD155 and CD112 induces cytotoxicity of NK cells and CD8+ T cells, as well as cytokine secretion. CD155 is expressed at cell junctions on primary vascular endothelial cells and is highly expressed on double-positive (DP) thymocytes.

Available Citation

Only one specific citation reference is provided in the search results: Kourepini, E. et al. (2016) published in the Journal of Immunology 196(9):3570-3580. However, the search results do not elaborate on the specific findings from this or other studies using clone 4.24.1.

To obtain comprehensive information about key findings from clone 4.24.1 citations, you would need to access specialized citation databases or scientific literature repositories that track the use of this specific antibody clone across published research.

Based on the available search results, specific dosing regimens for clone 4.24.1 are not detailed in the provided information. The search results indicate that this clone targets CD155 (PVR) in mice, but comprehensive dosing protocols across different mouse models have not been documented in the sources.

General Considerations for In Vivo Antibody Dosing

While specific information about clone 4.24.1 is limited, in vivo antibody dosing in mouse models typically varies based on several factors:

Target and mechanism of action significantly influence dosing strategies. For example, checkpoint blockade antibodies like anti-CTLA-4 typically use doses of 100-250 μg per mouse administered intraperitoneally every 3 days. Cell-depleting antibodies such as anti-CD4 (clone GK1.5) and anti-CD8 (clone 2.43) require 200-250 μg per mouse, administered 2-3 times per week.

Mouse strain and model type also affect dosing requirements. As noted for anti-IL-4 antibody (clone 11B11), standard dosing of 1 mg/mouse intraperitoneally every 4-5 days may need adjustment based on the specific mouse strain and tumor model being used.

Recommendations for Establishing Dosing Protocols

Without published data for clone 4.24.1, researchers would need to establish dosing empirically by:

• Starting with standard antibody doses in the 100-250 μg range for functional antibodies
• Monitoring target engagement and biological effects
• Adjusting based on the specific experimental endpoint and mouse model characteristics

For precise dosing information specific to clone 4.24.1 across different mouse models, consulting the antibody manufacturer or conducting pilot dose-finding studies would be necessary.